Vendor Intelligence Report: Shanghai Sigma Audley SSA
Published 12 Nov 2026. 40-page investigative report on who is behind Shanghai Sigma Audley SSA: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Across 228 Finnrick lab tests, Shanghai Sigma Audley SSA records 152 pass and 76 fail — a 67% overall pass rate. That headline hides a split catalog rather than a simple safe/unsafe vendor read. GHK-Cu and Retatrutide are the clearest stronger lanes; Sermorelin and BPC-157 are poor relative choices, and ratings compress further under stricter grading.
The bigger buyer problem is authentication. The report treats SSA as a brand lineage, not one seller: deregistered Chinese entities, old chemical-market profiles, multiple SSA-looking domains, and a live storefront whose own checkout code sends purchase actions to Oath Research. A federal pleading supplies the ownership chain for the checkout destination, while the operator of the SSA-branded clone remains unresolved.
The public trust layer does not cleanly solve that identity problem. The report documents one real older Janoshik result, but contrasts it with self-hosted verification pages, an invalid current Janoshik claim, Trustpilot-style reviews with no matching Trustpilot profile, and a same-day fake verifier network. Chainalysis precursor-commerce context and current precursor-category listings add legal and payment-rail risk separate from peptide purity.
The conclusion is directional: legacy SSA material should be assessed by product and batch, not by brand reputation. For current purchases, the report focuses on whether the buyer is actually reaching the vendor they think they are, who gets paid at checkout, why batch-release authority remains unverified, and where sterility/endotoxin evidence is missing.
Inside the full report:
- Per-product pass/fail rates and methodology-divergence charts for all 13 tested products
- Qichacha corporate filings for the Shanghai, Henan, and Shenzhen Sigma-linked entities
- SSA-to-Oath redirect-script analysis and a live add-to-cart checkout capture
- E.D. Va. complaint excerpts establishing the checkout destination ownership chain
- Hosting, registration, and content analysis of the Medu, PeptideDetective, and VendorInvestigator verification network
- Precursor-listing evidence, Chainalysis context, and the sterility/endotoxin evidence-gap review
Risk assessment
- Seller-identity switch and affiliate-clone risk — high: shanghaisigmaaudley.com names a deregistered Shanghai company in its terms but every purchase action tested redirects to oath.shop; the clone operator remains unidentified.
- Copycat / brand-confusion risk — high: sigmaaudley.site is flagged as a fraud/lookalike purchase path; multiple SSA-branded domains and Telegram personas exist with no authoritative official-channel list, reseller list, or anti-counterfeit system located.
- Fabricated verification and review risk — high: Medu, PeptideDetective, and VendorInvestigator share same-day infrastructure and identical SSA data; current SSA pages use self-hosted reports, a Trustpilot facade, and an invalid Janoshik #38736 claim.
- Product-specific quality risk — high: The weak lanes are Sermorelin 25.13%, CJC-1295 28.77%, BPC-157 36.3%, TB-500 37.96%, and Tesamorelin 39.3%; stronger lanes such as GHK-Cu, Retatrutide, Tirzepatide, and Ipamorelin still require batch verification.
- Sterility/endotoxin evidence risk — high: No lab-hosted sterility or endotoxin report from a recognized lab was found for current injectable products; the prior SSA Retatrutide sterility thread URL no longer resolves to that claim.
- Precursor / legal-continuity risk — high: Chainalysis links the predecessor Sigma Audley operation to fentanyl-precursor commerce, and the current SSA price list displays Norfentanyl, NPP, BMK/PMK, and related precursor entries.
- Domain-security instability risk — medium: Oath says oathresearch.com was hijacked in August 2026, shanghaisigmaaudley.net is on clientHold, and active SSA clones rotate across NiceNIC, Cloudflare, and Moldovan-hosted infrastructure.
- Payment and recourse risk — medium: SSA pages advertise crypto discounts, Cash App, bank transfer, and card rails while Oath affiliates can be paid in crypto; irreversible payments are materially riskier when the seller identity is unresolved.